The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Medication Treatment of Opioid Use Disorder
Open accessAbstract
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist). Methadone and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of other opioids. Naltrexone blocks the effects of opioid agonists. Oral methadone has the strongest evidence for effectiveness. Longer duration of treatment allows restoration of social connections and is associated with better outcomes. Treatments for OUD may be limited by poor adherence to treatment recommendations and by high rates of relapse and increased risk of overdose after leaving treatment. Treatment with methadone and buprenorphine has the additional risk of diversion and misuse of medication. New depot and implant formulations of buprenorphine and naltrexone have been developed to address issues of safety and problems of poor treatment adherence. For people with OUD who do not respond to these treatments, there is accumulating evidence for supervised injectable opioid treatment (prescribing pharmaceutical heroin). Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose. All medication-assisted treatment is limited by lack of access and by stigma. In seeking to stem the rising toll from OUD, expanding access to approved treatment such as methadone, for which there remains the best evidence of efficacy, may be the most useful approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
A 33-Year Follow-up of Narcotics Addicts
Hser, Y.-I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.503 · Cited by 848
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017) · BMJ · doi:10.1136/bmj.j760 · Cited by 534 · cited 1×
“Benzodiazepine use is common among people with OUD, and concurrent use of benzodiazepines and methadone is associated with an increased risk of fatal overdose and emergency room (ER) presentations (32, 33).”
BackgroundMcDonald, R., & Strang, J. (2016) · Addiction · doi:10.1111/add.13326 · Cited by 471
Self-citationHser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455 · cited 1×
“The impact of differences in retention has been demonstrated in a large trial which randomised participants to methadone or sublingual buprenorphine-naloxone (BNx) at flexible doses (42).”
BackgroundTorsade de Pointes Associated with Very-High-Dose Methadone
Krantz, M. J., Lewkowiez, L., Hays, H., Woodroffe, M. A., Robertson, A. D., & Mehler, P. S. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00010 · Cited by 426
Methadone maintenance at different dosages for opioid dependence
Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002208 · Cited by 406
McLellan, A. T., McKay, J. R., Forman, R., Cacciola, J., & Kemp, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01012.x · Cited by 389
The duration and correlates of addiction and treatment careers
Dennis, M. L., Scott, C. K., Funk, R., & Foss, M. A. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.10.013 · Cited by 352
Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.07.001 · Cited by 332
Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320
Does retention matter? Treatment duration and improvement in drug use
Zhang, Z., Friedmann, P. D., & Gerstein, D. R. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00354.x · Cited by 314 · cited 1×
“The duration of methadone treatment has been demonstrated to be a linear, nonthreshold predictor of outcome (6); longer episodes of treatment are associated with better outcomes.”
BackgroundClausen, T., Anchersen, K., & Waal, H. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.003 · Cited by 287
Haight, B. R., Learned, S. M., Laffont, C. M., Fudala, P. J., Zhao, Y., Garofalo, A. S., Greenwald, M. K., Nadipelli, V. R., Ling, W., Heidbreder, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32259-1 · Cited by 285
Mattick, R. P., Ali, R., White, J. M., O'Brien, S., Wolk, S., & Danz, C. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00335.x · Cited by 285
Strang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter, M. T., Lintzeris, N., Bell, J., Pirona, A., Oviedo-Joekes, E., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.149195 · Cited by 262
Self-citationQT-Interval Effects of Methadone, Levomethadyl, and Buprenorphine in a Randomized Trial
Wedam, E. F. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.22.2469 · Cited by 259
Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1052 · Cited by 255
Tanum, L., Solli, K. K., Latif, Z.-E.-H., Benth, J. Š., Opheim, A., Sharma-Haase, K., Krajci, P., & Kunøe, N. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3206 · Cited by 253
Rehm, J., Gschwend, P., Steffen, T., Gutzwiller, F., Dobler-Mikola, A., & Uchtenhagen, A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06529-1 · Cited by 235
Methadone Maintenance vs. Methadone Taper During Pregnancy: Maternal and Neonatal Outcomes
Jones, H. E., O'Grady, K. E., Malfi, D., & Tuten, M. (2008) · The American Journal on Addictions · doi:10.1080/10550490802266276 · Cited by 231
Variations in methadone treatment practices. Results from a national study
D’Aunno, T. A. (1992) · JAMA · doi:10.1001/jama.267.2.253 · Cited by 230
Hser, Y., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., et al. (2016) · Addiction · doi:10.1111/add.13238 · Cited by 221
Hadland, S. E., Bagley, S. M., Rodean, J., Silverstein, M., Levy, S., Larochelle, M. R., Samet, J. H., & Zima, B. T. (2018) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2018.2143 · Cited by 220
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic
WALSH, S. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00056-5 · Cited by 219
Kakko, J., Grönbladh, L., Svanborg, K. D., von Wachenfeldt, J., Rück, C., Rawlings, B., Nilsson, L.-H., & Heilig, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.797 · Cited by 197
Theory-based processes that promote the remission of substance use disorders
Moos, R. H. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2006.12.006 · Cited by 191
Comparing overdose mortality associated with methadone and buprenorphine treatment
Bell, J. R., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.03.020 · Cited by 182
Self-citationMaeyer, J. D., Vanderplasschen, W., Camfield, L., Vanheule, S., Sabbe, B., & Broekaert, E. (2011) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2011.03.009 · Cited by 179
Gossop, M., Marsden, J., Stewart, D., & Treacy, S. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00211-8 · Cited by 175
Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities
Wakeman, S. E., & Barnett, M. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1802741 · Cited by 175
Cycling in and out of treatment; participation in methadone treatment in NSW, 1990–2002
Bell, J. R., Burrell, T., Indig, D., & Gilmour, S. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.05.010 · Cited by 165
Self-citationTeesson, M., Mills, K. L., Ross, J. E., Darke, S. G., Williamson, A. B., & Havard, A. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.02029.x · Cited by 161
Strang, J., Hall, W., Hickman, M., & Bird, S. M. (2010) · BMJ · doi:10.1136/bmj.c4851 · Cited by 159
Self-citationEffect of Buprenorphine Dose on Treatment Outcome
Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.642758 · Cited by 159
Bell, J. R., Trinh, L. T. T., Butler, B., Randall, D., & RUBIN, G. L. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02627.x · Cited by 158
Self-citationKimber, J., Larney, S., Hickman, M., Randall, D., & Degenhardt, L. J. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00366-1 · Cited by 151
Kuhlman, J. J., LEVINE, B. S., Johnson, R. E., Fudala, P. J., & Cone, E. J. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.93454910.x · Cited by 131
Neale, J., & Strang, J. (2015) · Addiction · doi:10.1111/add.13027 · Cited by 117
Self-citationMcCowan, C., Kidd, B., & Fahey, T. P. (2009) · BMJ · doi:10.1136/bmj.b2225 · Cited by 115
Pharmacology of methadone and its isomers.
Inturrisi, C. E. (2006) · PubMed · Cited by 107
Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia
Kennare, R. M., Heard, A. R., & Chan, A. C. (2005) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2005.00379.x · Cited by 107
Lintzeris, N., Bell, J. R., Bammer, G., Jolley, D. J., & Rushworth, R. L. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00215.x · Cited by 102
Self-citationMethadone in Primary Care — One Small Step for Congress, One Giant Leap for Addiction Treatment
Samet, J. H., Botticelli, M. P., & Bharel, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1803982 · Cited by 99
Rosenthal, R. N., Ling, W. W., Casadonte, P. P., Vocci, F. J., Bailey, G. L., Kampman, K. M., Patkar, A. A., Chavoustie, S. E., Blasey, C. M., Sigmon, S. C., et al. (2013) · Addiction · doi:10.1111/add.12315 · Cited by 98
McDonald, R., Lorch, U., Woodward, J., Bosse, B., Dooner, H., Mundin, G., Smith, K. J., & Strang, J. (2017) · Addiction · doi:10.1111/add.14033 · Cited by 98
Self-citationOverdose after detoxification: A prospective study☆
Wines, J. D., Saitz, R., Horton, N. J., Lloyd-Travaglini, C. A., & Samet, J. H. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.12.019 · Cited by 95
Teruya, C., Schwartz, R. P., Mitchell, S. G., Hasson, A. L., Thomas, C., Buoncristiani, S. H., Hser, Y., Wiest, K. L., Cohen, A. J., Glick, N., et al. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.921743 · Cited by 90
Pharmacological maintenance treatments of opiate addiction
Bell, J. R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12051 · Cited by 86
Self-citationJones, H. E., Chisolm, M. S., Jansson, L. M., & Terplan, M. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03811.x · Cited by 73
Russolillo, A., Moniruzzaman, A., McCandless, L. C., Patterson, M., & Somers, J. M. (2017) · Addiction · doi:10.1111/add.14059 · Cited by 68
Oviedo‐Joekes, E., Guh, D. P., Brissette, S., Marsh, D. C., Nosyk, B., Krausz, M. R., Anis, A. H., & Schechter, M. T. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.003 · Cited by 45
Naltrexone in the treatment of heroin dependence: a literature review
Tucker, T., & Ritter, A. J. (2000) · Drug and Alcohol Review · doi:10.1080/09595230096174 · Cited by 44
Degenhardt, L. J., Larance, B., Bell, J. R., WINSTOCK, A. R., Lintzeris, N., Ali, R. L., Scheuer, N., & Mattick, R. P. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02729.x · Cited by 43
Self-citationZhang, L., Zou, X., Zhang, D., Li, X., Zhao, P., & Ling, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139942 · Cited by 37
Saucier, R., Wolfe, D., & Dasgupta, N. (2018) · Drug Safety · doi:10.1007/s40264-018-0653-3 · Cited by 34
Excess mortality among opioid-using patients treated with oral naltrexone in Australia.
Degenhardt, L., Larney, S., Kimber, J., Farrell, M., & Hall, W. (2015) · Drug and Alcohol Review · doi:10.1111/dar.12205 · Cited by 32
Supervised Injectable Opioid Treatment for the Management of Opioid Dependence
Bell, J., Belackova, V., & Lintzeris, N. (2018) · Drugs · doi:10.1007/s40265-018-0962-y · Cited by 32
Self-citationManagement of women treated with buprenorphine during pregnancy
Alto, W. A., & O’Connor, A. B. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.04.001 · Cited by 31
Mundin, G., McDonald, R., Smith, K. J., Harris, S., & Strang, J. (2017) · Addiction · doi:10.1111/add.13849 · Cited by 25
Self-citationCarrieri, P., Vilotitch, A., Nordmann, S., Lions, C., Michel, L., Mora, M., Morel, A., Maradan, G., Spire, B., & Roux, P. (2017) · The International journal on drug policy · doi:10.1016/j.drugpo.2016.08.005 · Cited by 13
The cost of concordance with opiate substitution treatment guidelines
Barnett, P. G., Trafton, J. A., & Humphreys, K. N. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.05.012 · Cited by 11
Cited by
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
Powers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00347 · Cited by 15
Gold, M. S., Blum, K., Bowirrat, A., Pinhasov, A., Bagchi, D., A. Dennen, C., K. Thanos, P., Hanna, C., Lewandrowski, K.-U., Sharafshah, A., et al. (2024) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps.1918 · Cited by 9
Metadata
- Authors
- Bell, J., & Strang, J.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 87
- Issue
- 1
- Pages
- 82-88
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2956150492
- Cited by
- 328
- References
- 64
- FWCI
- 22.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.